Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Regulatory agencies (FDA and EMA) reviewed the evidence and found no causal relationship
Add to cart now
The $399 price applies to the standard four-week GHK-Cu program
Unlike earlier single or dual incretin-based therapies, Retatrutide is known as a triple hormone receptor agonist, acting simultaneously on GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
ISBN 978-92-4-154612-6
US$ 23.87
US$ 28.25
US$ 23.74
US$ 21.59
US$ 20.56
US$ 26.65
